Second Autologous Stem Cell Transplant as Salvage in Multiple Myeloma – The Oregon Health and Science University Experience

Though the available number and efficacy of novel agents for multiple myeloma (MM) have grown in recent years, it remains an incurable disease with relapse inevitable in nearly all patients. Autologous stem cell transplantation (ASCT) after induction chemotherapy remains the standard of care for transplant-eligible patients, with randomized studies demonstrating median progression-free survival (PFS) greater than 4 years1. Options at relapse have similarly continued to improve with numerous agents and combinations now available; in some salvage settings treatment can yield a PFS in excess of 3 years2.

Source: Clinical Lymphoma, Myeloma and Leukemia - September 14, 2021 Category: Hematology Authors: Derek Galligan, Staci Williamson, Jessie Myers, Rebecca Silbermann, Eva Medvedova, Sarah Nagle, Levanto Schachter, Andy Chen, Emma Scott, Richard Maziarz Source Type: research